[go: up one dir, main page]

MX380850B - Composiciones solubles en agua que comprenden cannabinoides purificadas - Google Patents

Composiciones solubles en agua que comprenden cannabinoides purificadas

Info

Publication number
MX380850B
MX380850B MX2019002198A MX2019002198A MX380850B MX 380850 B MX380850 B MX 380850B MX 2019002198 A MX2019002198 A MX 2019002198A MX 2019002198 A MX2019002198 A MX 2019002198A MX 380850 B MX380850 B MX 380850B
Authority
MX
Mexico
Prior art keywords
water
soluble compositions
purified cannabinoids
compositions
temperature
Prior art date
Application number
MX2019002198A
Other languages
English (en)
Other versions
MX2019002198A (es
Inventor
Kurt Aron Levy
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of MX2019002198A publication Critical patent/MX2019002198A/es
Publication of MX380850B publication Critical patent/MX380850B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Estas divulgaciones se refieren a nuevas composiciones y métodos para la generación de formulaciones cannabinoides. En una modalidad, la divulgación proporciona composiciones solubles en agua que comprenden un primer cannabinoide purificado y la vitamina E TPGS. En una modalidad, la descripción en el presente documento comprende un método de fabricación de polvos que comprenden material de calefacción a una primera temperatura y una segunda temperatura.
MX2019002198A 2016-08-29 2017-08-29 Composiciones solubles en agua que comprenden cannabinoides purificadas MX380850B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380954P 2016-08-29 2016-08-29
PCT/US2017/049219 WO2018044953A1 (en) 2016-08-29 2017-08-29 Water soluble compositions comprising purified cannabinoids

Publications (2)

Publication Number Publication Date
MX2019002198A MX2019002198A (es) 2019-08-16
MX380850B true MX380850B (es) 2025-03-12

Family

ID=61301487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002198A MX380850B (es) 2016-08-29 2017-08-29 Composiciones solubles en agua que comprenden cannabinoides purificadas

Country Status (10)

Country Link
US (6) US10568865B2 (es)
EP (1) EP3503875A4 (es)
CN (1) CN110177543A (es)
AU (1) AU2017319320B2 (es)
BR (1) BR112019003815A2 (es)
CA (1) CA3034004C (es)
CL (1) CL2019000474A1 (es)
CO (1) CO2019002744A2 (es)
MX (1) MX380850B (es)
WO (1) WO2018044953A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034004C (en) 2016-08-29 2021-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
WO2019130201A1 (en) * 2017-12-29 2019-07-04 Buzzelet Development And Technologies Ltd Purified cannabis extracts and methods for production thereof
EP3743055B1 (en) 2018-01-23 2024-03-06 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds
CN112969452A (zh) 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
WO2019211771A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Water soluble and water dispersible formulations of cannabinoids
WO2020150616A1 (en) * 2019-01-17 2020-07-23 Synthonics, Inc. Solid micellar compositions of cannabinoid acids
US10993928B2 (en) * 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
US10780075B1 (en) 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
MX2022001802A (es) * 2019-08-10 2022-03-11 Locus Ip Co Llc Metodos para incrementar la biodisponibilidad de medicamentos farmaceuticos y de venta libre.
JP2022548377A (ja) * 2019-09-18 2022-11-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 吸入による送達のためのカンナビノイドの組成物
US11186944B1 (en) * 2019-10-23 2021-11-30 Sam Salem And Son, Llc Method of making polyester fabric treated with a CBD powder
CN112915121A (zh) * 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
US20220142969A1 (en) * 2019-12-31 2022-05-12 Soluscience, Llc Water-soluble cannabinoid formulations and methods of their making
CA3078970A1 (en) * 2020-04-16 2021-10-16 National Research Council Of Canada Water soluble formulations containing cannabinoids
CN114748429A (zh) * 2020-12-29 2022-07-15 汉义生物科技（北京）有限公司 一种水溶性大麻素制剂及其制备方法
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
EP4346763A1 (en) * 2021-05-31 2024-04-10 Cannabotech Ltd. Compositions comprising a cannabinoid and uses thereof
AU2023224515A1 (en) * 2022-02-28 2024-09-19 Emyria Cannabinoid dosage form
DE202022102593U1 (de) 2022-05-12 2022-05-30 DÖHLER GmbH Zusammensetzung mit Cannabinoiden und deren Verwendung

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837228A (en) 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20030101902A1 (en) 2001-12-04 2003-06-05 Ann Reitnauer Hot melt inks
AU2003240824B9 (en) * 2002-05-31 2008-09-25 University Of Mississippi Transmucosal delivery of cannabinoids
BRPI0415741B1 (pt) 2003-11-07 2013-07-23 composições de tabaco e métodos de fabricação de uma composição de tabaco
GB0329635D0 (en) 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
FR2885619B1 (fr) 2005-05-13 2011-02-11 Imaje Sa Composition d'encre liquide, alimentaire, ingerable pour l'impression par jet d'encre
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
US7923026B2 (en) 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
US20090098192A1 (en) 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
DE102009019322A1 (de) 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
US20110052694A1 (en) 2009-08-31 2011-03-03 Alltranz Inc. Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
WO2011135591A2 (en) 2010-04-29 2011-11-03 Shasun Pharmaceuticals Limited Novel tablet composition of polyallylamine polymers
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
JP6368242B2 (ja) 2011-10-06 2018-08-01 ノバルティス アーゲー ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
WO2014100231A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
EP4137142A1 (en) 2013-03-14 2023-02-22 Purple Mundo, Inc. Bioactive concentrates and uses thereof
CN105050417B (zh) 2013-03-29 2018-05-29 洲际大品牌有限责任公司 透明和半透明的液体夹心糖果、其制备方法、不含食糖的液体可食组合物及其用途
US9056049B2 (en) 2013-05-30 2015-06-16 Chin Yuan Huang Micro-particle comprising a protein extract from sweet potato for extending satiety and controlling blood glucose and lipid levels
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
EP3001811B1 (en) 2013-10-29 2016-12-21 Echo Pharmaceuticals B.V. Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
JP2016537412A (ja) 2013-10-31 2016-12-01 フル スペクトラム ラボラトリーズ，エルティーディー． テルペン及びカンナビノイドの製剤
WO2015074137A1 (en) 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
US20160022627A2 (en) 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
US9861611B2 (en) * 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
WO2016109624A1 (en) 2014-12-30 2016-07-07 University Of Houston System Pharmaceutical compositions
US20170266153A1 (en) 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
US20160250270A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
CA3034004C (en) 2016-08-29 2021-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
WO2018142403A1 (en) 2017-02-02 2018-08-09 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
PE20200731A1 (es) 2017-09-28 2020-07-23 Canopy Growth Corp Composiciones de cannabinoides comestibles
CA3104795A1 (en) 2018-06-28 2020-01-02 Canopy Growth Corporation Compositions and methods for agonizing the cb2 receptor

Also Published As

Publication number Publication date
EP3503875A4 (en) 2020-06-24
MX2019002198A (es) 2019-08-16
US20190183853A1 (en) 2019-06-20
BR112019003815A2 (pt) 2019-05-21
US20200121637A1 (en) 2020-04-23
CL2019000474A1 (es) 2019-05-10
US20200253924A1 (en) 2020-08-13
CA3034004C (en) 2021-08-03
US20210308098A1 (en) 2021-10-07
US11510897B2 (en) 2022-11-29
WO2018044953A1 (en) 2018-03-08
US20210308097A1 (en) 2021-10-07
CA3034004A1 (en) 2018-03-08
US10842773B2 (en) 2020-11-24
AU2017319320B2 (en) 2023-08-03
US10722490B2 (en) 2020-07-28
AU2017319320A1 (en) 2019-04-04
US10568865B2 (en) 2020-02-25
EP3503875A1 (en) 2019-07-03
CO2019002744A2 (es) 2019-04-12
CN110177543A (zh) 2019-08-27
US20210000791A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MX380850B (es) Composiciones solubles en agua que comprenden cannabinoides purificadas
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
CO2017004974A2 (es) Extractos de cannabis y métodos de preparación.
EP3886883A4 (en) WATER SOLUBLE FORMULATIONS OF CANNABINOIDS OR COMPOUNDS DERIVED FROM CANNABIS, METHODS OF MAKING THEM AND METHODS OF USE
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
MX2017011884A (es) Composiciones cosmeticas topicas contra radicales libres.
CY1123477T1 (el) Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων
MX378687B (es) Formulacion de vitamina soluble en grasa.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
CO2021001057A2 (es) Composición y método para el ahorro de opioides
MX2018002849A (es) Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
DOP2017000085A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
CO2021002085A2 (es) Composiciones de curcuminoides
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
MX2016003215A (es) Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion.
UY38829A (es) Cannabinoides solubles en agua
NZ756307A (en) Formulations of cannabinoids for the treatment of acne
LT3565602T (lt) Naujas būdas, skirtas vandenyje tirpaus forskolino paruošimui
CO2017002963A2 (es) Espiro-tiazolonas
BR112018012030A2 (pt) composição para redução da frequência de urinação, método de produção e uso da mesma